Diamond Therapeutics
Diamond Therapeutics is a private Canadian clinical-stage company pioneering sub-perceptual (non-hallucinogenic) psilocybin therapy. Their approach focuses on low-dose psilocybin that does not produce psychedelic experiences, enabling at-home outpatient administration — a differentiated strategy from the clinic-based, high-dose psychedelic-assisted therapy model. Founded in 2018 by CEO Judith Blumstock, Diamond completed a Phase 1 single ascending dose study in healthy volunteers (n=56, 7 cohorts, December 2022) establishing a safe non-hallucinogenic dose range. Their Phase 2a GAD programme received Health Canada approval in January 2023 — the first Health Canada NOL for a psychedelic trial in GAD — and enrolled first patients at Kingston Health Sciences Centre in 2025 in the first-ever at-home microdose psilocybin study. A parallel FDA-authorized Phase 2 demoralization trial is also underway at UAB. Diamond is funded by private investors and non-dilutive public grants, including a $1.1M+ CQDM/Brain Canada drug discovery consortium launched in May 2025.
Development Programmes
1Low-Dose Psilocybin
PsilocybinGeneralised anxiety disorder / demoralization
Programme Tracker
Anxiety Disorders
Phase 2a ongoing at Kingston Health Sciences Centre (KHSC), Ontario; first-ever Health Canada-approved at-home microdose psychedelic trial; first patient July 30, 2025
Milestones
Phase I topline
CompletedActual: Dec 7, 2022
Phase 1 complete: safe, tolerable, non-hallucinogenic dose range established in 56 subjects (7 cohorts); no AEs precluding outpatient use
Why it matters: Phase 1 demonstrated that sub-perceptual (non-hallucinogenic) psilocybin doses are safe and tolerable, laying the groundwork for take-home daily microdosing trials without clinic supervision.
Phase II started
CompletedActual: Jul 30, 2025
Phase 2a first patient dosed at KHSC (July 30, 2025); 40–60 patients; daily take-home sub-perceptual dosing x4 weeks + OLE
Why it matters: First Phase 2 clinical data from a home-administered daily microdosing psilocybin schedule in GAD patients. Results will inform whether sub-perceptual dosing provides therapeutic benefit without the full psychedelic session model.
Watch next: Phase 2a primary endpoint results (anxiety reduction at 4 weeks + OLE follow-up)
Regulatory review accepted
CompletedActual: Jan 24, 2023
Health Canada No Objection Letter for Phase 2a GAD trial — first-ever HC approval for psychedelic Phase 2
Why it matters: First Health Canada approval of a Phase 2 psychedelic trial and the first approved at-home microdose psychedelic study globally — a regulatory milestone for the entire field.
Recorded Events
Jul 30, 2025: Phase II started
Jan 24, 2023: Regulatory review accepted
Dec 7, 2022: Phase I topline
Palliative & End-of-Life Distress
Phase 2a ongoing at UAB (NCT06341426); 60 patients; 5-week randomised double-blind; PI: Dr. Peter Hendricks
Milestones
Phase II started
CompletedActual: Oct 17, 2023
First patient enrolled at UAB for demoralization study (NCT06341426); FDA-authorised IND
Why it matters: Demoralization (loss of meaning/hope) in medically ill patients is a distinct syndrome with no approved treatment. Diamond's sub-perceptual dosing approach tests whether regular low-dose psilocybin can address existential suffering without a macro-dose session.
Watch next: Primary endpoint results from NCT06341426
Recorded Events
Oct 17, 2023: Phase II started
Quick Facts
- Type
- Private Biotech
- Lead Stage
- Phase II
- Website
- Visit